Novartis (NVS) Competitors

$145.11 -0.92 (-0.63%)

Closing price 03:59 PM Eastern

Extended Trading

$145.21 +0.09 (+0.06%)

As of 04:32 PM Eastern

NVS vs. AZN, NVO, SNY, GSK, and TAK

Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include Astrazeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does Novartis compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novartis (NYSE:NVS) are both large-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Astrazeneca has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novartis	24.87%	38.82%	15.16%

Astrazeneca currently has a consensus price target of $205.33, suggesting a potential upside of 12.87%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 2.70%. Given Astrazeneca's stronger consensus rating and higher possible upside, research analysts clearly believe Astrazeneca is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Novartis has lower revenue, but higher earnings than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.31
Novartis	$56.58B	4.89	$13.98B	$6.98	20.79

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Novartis had 3 more articles in the media than Astrazeneca. MarketBeat recorded 21 mentions for Novartis and 18 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 1.24 beat Novartis' score of 0.59 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Novo Nordisk A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Novartis	24.87%	38.82%	15.16%

Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.8%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$327.80B	0.63	$15.51B	$4.26	10.88
Novartis	$56.58B	4.89	$13.98B	$6.98	20.79

Novo Nordisk A/S currently has a consensus price target of $65.56, suggesting a potential upside of 41.50%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 2.70%. Given Novo Nordisk A/S's higher possible upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Novo Nordisk A/S had 51 more articles in the media than Novartis. MarketBeat recorded 72 mentions for Novo Nordisk A/S and 21 mentions for Novartis. Novartis' average media sentiment score of 0.59 beat Novo Nordisk A/S's score of 0.52 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	28 Very Positive mention(s)	14 Positive mention(s)	18 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Positive
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novartis compare to Sanofi?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novartis	24.87%	38.82%	15.16%

Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.2%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Sanofi pays out 49.4% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.87
Novartis	$56.58B	4.89	$13.98B	$6.98	20.79

Sanofi currently has a consensus price target of $51.00, suggesting a potential upside of 20.00%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 2.70%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Novartis had 13 more articles in the media than Sanofi. MarketBeat recorded 21 mentions for Novartis and 8 mentions for Sanofi. Novartis' average media sentiment score of 0.59 beat Sanofi's score of 0.40 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novartis beats Sanofi on 13 of the 19 factors compared between the two stocks.

How does Novartis compare to GSK?

Novartis (NYSE:NVS) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Novartis has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$56.58B	4.89	$13.98B	$6.98	20.79
GSK	$32.78B	3.08	$7.54B	$3.85	12.94

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
GSK	17.82%	44.28%	11.49%

13.1% of Novartis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.6%. Novartis pays out 44.1% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Novartis had 19 more articles in the media than GSK. MarketBeat recorded 21 mentions for Novartis and 2 mentions for GSK. GSK's average media sentiment score of 1.38 beat Novartis' score of 0.59 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis currently has a consensus price target of $141.20, suggesting a potential downside of 2.70%. GSK has a consensus price target of $53.00, suggesting a potential upside of 6.39%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

Summary

Novartis beats GSK on 12 of the 18 factors compared between the two stocks.

How does Novartis compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Novartis has a consensus price target of $141.20, indicating a potential downside of 2.70%. Given Novartis' higher probable upside, analysts plainly believe Novartis is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Takeda Pharmaceutical has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Novartis has a net margin of 24.87% compared to Takeda Pharmaceutical's net margin of 2.58%. Novartis' return on equity of 38.82% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.58%	10.60%	5.21%
Novartis	24.87%	38.82%	15.16%

Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.1%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Takeda Pharmaceutical pays out 208.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 44.1% of its earnings in the form of a dividend.

In the previous week, Novartis had 19 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Novartis and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.79 beat Novartis' score of 0.59 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has lower revenue, but higher earnings than Takeda Pharmaceutical. Novartis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.46T	0.01	$712.33M	$0.24	68.06
Novartis	$56.58B	4.89	$13.98B	$6.98	20.79

Summary

Novartis beats Takeda Pharmaceutical on 12 of the 18 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVS vs. The Competition

Export

Metric	Novartis	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$276.89B	$289.19B	$6.18B	$22.92B
Dividend Yield	2.12%	2.83%	2.78%	4.02%
P/E Ratio	20.79	25.83	20.66	28.94
Price / Sales	4.89	4.76	527.03	24.54
Price / Cash	13.60	12.33	27.81	19.21
Price / Book	6.58	7.28	9.77	4.65
Net Income	$13.98B	$11.61B	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-5.72%	-1.91%	6.33%	3.96%
1 Year Performance	33.52%	22.86%	41.88%	28.96%

Novartis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVS Novartis	3.4938 of 5 stars	$145.11 -0.6%	$141.20 -2.7%	+34.3%	$276.89B	$56.58B	20.79	75,267	Analyst Revision
AZN Astrazeneca	4.0489 of 5 stars	$184.97 +2.1%	$205.33 +11.0%	N/A	$286.86B	$60.44B	27.77	96,100	Positive News Analyst Revision
NVO Novo Nordisk A/S	4.6076 of 5 stars	$45.82 +2.1%	$65.56 +43.1%	-30.0%	$204.57B	$46.80B	13.20	69,505	Trending News Earnings Report Analyst Revision
SNY Sanofi	4.0713 of 5 stars	$43.77 +0.9%	$51.00 +16.5%	-13.3%	$106.76B	$49.35B	12.23	74,846	Analyst Revision
GSK GSK	3.4213 of 5 stars	$50.57 +0.4%	$53.00 +4.8%	+37.5%	$102.62B	$43.07B	13.14	66,841	Positive News Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVS) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and TAK

How does Novartis compare to Astrazeneca?

Summary

How does Novartis compare to Novo Nordisk A/S?

Summary

How does Novartis compare to Sanofi?

Summary

How does Novartis compare to GSK?

Summary

How does Novartis compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and TAK

How does Novartis compare to Astrazeneca?

Which has more risk & volatility, AZN or NVS?

Is AZN or NVS more profitable?

Do analysts rate AZN or NVS?

Which has preferable earnings and valuation, AZN or NVS?

Do institutionals & insiders believe in AZN or NVS?

Does the media favor AZN or NVS?

Is AZN or NVS a better dividend stock?

Summary

How does Novartis compare to Novo Nordisk A/S?

Which has more risk & volatility, NVO or NVS?

Is NVO or NVS more profitable?

Is NVO or NVS a better dividend stock?

Which has preferable earnings and valuation, NVO or NVS?

Do analysts rate NVO or NVS?

Do institutionals & insiders believe in NVO or NVS?

Does the media favor NVO or NVS?

Summary

How does Novartis compare to Sanofi?

Which has more risk and volatility, SNY or NVS?

Is SNY or NVS more profitable?

Is SNY or NVS a better dividend stock?

Which has better earnings & valuation, SNY or NVS?

Do analysts rate SNY or NVS?

Do insiders and institutionals believe in SNY or NVS?

Does the media refer more to SNY or NVS?

Summary

How does Novartis compare to GSK?

Which has more volatility and risk, NVS or GSK?

Which has preferable earnings and valuation, NVS or GSK?

Is NVS or GSK more profitable?

Do insiders & institutionals have more ownership in NVS or GSK?

Is NVS or GSK a better dividend stock?

Does the media prefer NVS or GSK?

Do analysts rate NVS or GSK?

Summary

How does Novartis compare to Takeda Pharmaceutical?

Do institutionals & insiders have more ownership in TAK or NVS?

Do analysts prefer TAK or NVS?

Which has more risk and volatility, TAK or NVS?

Is TAK or NVS more profitable?

Is TAK or NVS a better dividend stock?

Does the media favor TAK or NVS?

Which has better earnings & valuation, TAK or NVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools